JNJ is outperforming ABBV year-to-date, and the gap is not trivial. Johnson & Johnson is up roughly 17% in 2026. AbbVie is flat for the year as of June 12, but has been rallying. On the surface, that makes JNJ the obvious choice. But surface readings in biopharma are dangerous. The underlying growth rates, pipeline trajectories, and acquisition strategies tell a more complicated story — one that could favor AbbVie if investors are willing to look past short-term price action.

JNJ is a diversified healthcare conglomerate operating across Innovative Medicine and MedTech. It is approaching $100 billion in annual revenue and has 64 consecutive years of dividend increases. The company has become a more defined biopharma investment since its divestment of Kenvue (NYSE: KVUE) in 2023.

AbbVie is a more concentrated bet: a biopharma pure-play that survived the Humira patent cliff by spending aggressively on acquisitions and building a next-generation immunology franchise around Skyrizi and Rinvoq.

The questions investors need to answer are straightforward. Does JNJ’s diversification justify a premium over AbbVie’s superior revenue growth rate? And does AbbVie’s acquisition-heavy balance sheet carry risks that JNJ’s more conservative posture avoids? What follows is a direct comparison of both companies across the metrics that matter most in a rotation trade.

Two Giants, Different Architectures

Johnson & Johnson delivered Q1 2026 reported sales growth of 9.9% to $24.1 billion, with adjusted EPS of $2.70, and raised its full-year 2026 guidance to estimated reported sales of $100.8 billion — a 7% increase at the midpoint. The company currently has 28 platforms or products generating at least $1 billion in annual revenue and is projecting double-digit growth by the end of the decade.

The MedTech segment provides something no pure-play pharma can replicate: a structural hedge against drug-cycle risk, with exposure to electrophysiology, orthopedics, and surgical robotics that generates revenue regardless of what happens in any single pipeline.

AbbVie’s architecture is narrower, but its growth rate is faster. Q1 2026 worldwide net revenues reached $15.0 billion, an increase of 12.4% on a reported basis, with the immunology portfolio rising 16.4% to $7.29 billion. Full-year 2026 adjusted EPS guidance stands at $14.37 to $14.57, reflecting another year of robust growth following record net sales in 2025. The company has fully cleared the Humira cliff — the drug that once generated more than $20 billion annually has been replaced, not propped up.

The Acquisition Scorecards

Both companies have been active acquirers, but the scale and philosophy differ sharply. JNJ’s latest move is surgical. On June 8, 2026, Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody-conjugate platform, focused on KRAS-driven tumors.

The Firelink DAC platform is designed to deliver a selective protein degrader to tumor cells while avoiding healthy cells. Rather than buying a commercial product, JNJ is acquiring a platform—one that could yield multiple oncology candidates targeting a historically undruggable mutation. The deal is modest in dollar terms but meaningful as a signal of where JNJ sees the next wave of cancer therapy heading.

AbbVie has taken a different approach: serial, large-scale acquisitions designed to diversify entirely away from any single therapeutic area. The 2020 acquisition of Allergan created leadership positions in immunology and neuroscience, as well as a global aesthetics franchise built around Botox and Juvederm.

That was followed by two transformative 2024 deals: the $8.7 billion acquisition of Cerevel Therapeutics, adding a neuroscience pipeline targeting psychiatric and neurological disorders, and the $10.1 billion acquisition of ImmunoGen, bringing in ELAHERE, a first-in-class antibody-drug conjugate approved for platinum-resistant ovarian cancer. The cumulative M&A spend over five years exceeds $60 billion. The payoff is a genuinely diversified revenue base. The cost is a leveraged balance sheet that requires execution to justify.

The Growth Picture

AbbVie’s near-term story runs through two drugs. Skyrizi sales grew 29.2% year over year to $4.48 billion in Q1 2026, while Rinvoq generated $2.12 billion, up 20.2%. AbbVie now expects full-year Skyrizi revenues of approximately $21.6 billion and Rinvoq revenues of approximately $10.2 billion, with the two drugs projected to deliver combined growth of more than 20% in 2026. Management believes the sell-side is still underestimating the ceiling — CEO Robert Michael stated that consensus peaks Skyrizi at $33 billion in 2031, while AbbVie expects to exceed that figure.

JNJ’s growth is broader but more measured. Innovative Medicine worldwide operational sales grew 7.4%, driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT in oncology, TREMFYA in immunology, and SPRAVATO in neuroscience, partially offset by biosimilar pressure on STELARA. The diversification that limits upside also limits downside — no single product failure is capable of derailing the enterprise.

Which Biopharma Stock Wins From Here?

JNJ’s 2026 outperformance reflects its defensive characteristics. Low beta, two business segments, and a balance sheet that carries JNJ through litigation cycles — including ongoing talc liability — make it the natural first landing spot when investors exit high-multiple growth stocks. That trade has played out this year.

But defensive leadership rarely persists indefinitely. AbbVie’s immunology engines are still accelerating, its neuroscience and oncology acquisitions are beginning to contribute, and its 2026 adjusted EPS guidance implies a valuation that looks reasonable relative to its growth rate. If rotation into healthcare broadens from defensive positioning into genuine growth-seeking, AbbVie’s superior top-line momentum becomes a more compelling argument.

Both biopharma stocks are on the radar of investors waiting for the sector to catch a bid. JNJ is the anchor trade; AbbVie is the growth lever. Which wins in the second half of 2026 depends largely on whether this rotation stays defensive or gets aggressive.

Between rising geopolitical tensions and ongoing economic uncertainty, fear has started to creep back into the market. As a result, some investors are choosing to pull their money out altogether. However, this is often a costly mistake. Selling during periods of volatility can lock in losses and prevent investors from participating in the eventual recovery.

Why Dividend ETFs Can Help Reduce Market Volatility

It’s important to remember that markets have endured far worse pullbacks in the past—and have consistently bounced back over time. Instead of abandoning the market, a more effective strategy is to stay invested while reducing risk through diversification. One way to do that is by adding income-generating dividend ETFs to your portfolio. These funds can help investors generate cash flow while maintaining exposure to equities during uncertain periods.

Fidelity High Dividend ETF Combines Income and Growth

The Fidelity High Dividend ETF (NYSEARCA: FDVV) is a solid choice for investors seeking a balance of income and growth. With an expense ratio of just 0.16% and a yield of about 3.26%, FDVV tracks the Fidelity High Dividend Index. This index focuses on large- and mid-cap companies that not only pay dividends but are also expected to grow those payouts over time.

The fund holds a diversified mix of well-established companies across multiple sectors. Some of its top holdings include Apple Inc. (NASDAQ: AAPL), Microsoft (NASDAQ: MSFT), NVIDIA (NASDAQ: NVDA), JPMorgan Chase (NYSE: JPM), Visa Inc. (NYSE: V), Exxon Mobil (NYSE: XOM), Philip Morris International (NYSE: PM), and Procter & Gamble (NYSE: PG).

iShares Core High Dividend ETF Focuses on Stability

Another strong option is the iShares Core High Dividend ETF (NYSEARCA: HDV), which tracks an index of relatively high-dividend-paying U.S. equities.

HDV stands out for its low expense ratio of 0.08% and a yield of around 3.3%. The fund focuses on financially healthy companies with strong dividend sustainability, making it an attractive option for conservative investors.

The ETF holds about 75 companies, including major names like Exxon Mobil, Johnson & Johnson (NYSE: JNJ), Chevron Corporation (NYSE: CVX), AbbVie (NYSE: ABBV), AT&T (NYSE:T), and The Coca-Cola Company (NYSE: KO). Because of its focus on stable, high-quality dividend payers, HDV can help reduce volatility while providing consistent income—an appealing combination during uncertain market conditions.

JPMorgan Nasdaq Equity Premium Income ETF Offers Double-Digit Yield Potential

For investors seeking higher income potential, the JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: JEPQ) is one of the most compelling options available today.

JEPQ offers a significantly higher yield—around 10%—and is designed to deliver monthly income while maintaining exposure to U.S. large-cap growth stocks.

What sets JEPQ apart is its use of a covered-call strategy. The fund generates income by selling options on Nasdaq-linked securities while holding a portfolio of large-cap growth companies. The premiums collected from these options are then distributed to investors, creating a steady stream of income.

This approach allows investors to benefit from income generation while still participating, to some extent, in the growth potential of the Nasdaq. However, it’s worth noting that covered-call strategies can limit upside during strong bull markets.

Dividend ETFs Can Help Investors Stay Defensive Without Leaving the Market

In times of market volatility, staying invested is crucial. Rather than reacting emotionally and exiting the market, investors can strengthen their portfolios by incorporating diversified, income-producing dividend ETFs.

Funds like FDVV, HDV, and JEPQ offer different approaches to balancing income, diversification, and downside protection. Some prioritize dividend growth and stability, while others focus on maximizing monthly income through option-based strategies. For investors looking to remain invested during uncertain conditions, dividend ETFs can provide a practical way to reduce portfolio volatility while continuing to generate cash flow and participate in long-term market growth.

With geopolitical tensions surrounding Iran creating uncertainty, no one knows how long volatility will persist. That’s forcing investors to shift toward defensive strategies that emphasize stability, income, and diversification over aggressive growth.

Instead of sitting in cash or trying to time the market, investors may find better opportunities in safe ETFs that provide steady exposure to high-quality assets—some of which follow strategies favored by Warren Buffett.

Why Safe ETFs Make Sense in Volatile Markets

During uncertain periods, the priority shifts from maximizing returns to preserving capital and generating consistent income. Safe ETFs offer:

• Broad diversification across sectors
• Exposure to high-quality companies
• Lower costs compared to active funds
• Reliable dividend income in some cases

These characteristics make them ideal tools for navigating unpredictable markets while staying invested.

Vanguard S&P 500 ETF (VOO): Broad Market Stability

“Over the years, I’ve often been asked for investment advice,” Buffett wrote in a 2016 shareholder letter. “My regular recommendation has been a low-cost S&P 500 index fund.” With that, Buffett has named the Vanguard S&P 500 ETF (NYSEARCA: VOO) as one way to invest.

What makes the VOO ETF attractive is that it measures the performance of the S&P 500 and includes both value and growth stocks across multiple sectors. This broad exposure helps reduce risk tied to any single industry. Some of its top holdings include: NVIDIA Corp. (NASDAQ: NVDA), Microsoft Corp. (NASDAQ: MSFT), Apple (NASDAQ: AAPL), Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOGL), and Berkshire Hathaway (NYSE: BRK.B), to name a few.

It offers a low-cost way to safely diversify by tracking the biggest companies, making it an ideal “set it and forget it” trade. In addition, with an expense ratio of 0.03%, the ETF also pays a quarterly yield. 

VanEck Morningstar Wide Moat ETF (MOAT): Quality Over Everything

If you follow Warren Buffett, you know he prefers companies with a wide economic moat—businesses that can defend their profits against competitors over long periods.

In fact, if you want to invest in companies attractive to the billionaire, make sure they are:

• Simple companies that are easy to understand
• Companies with predictable and proven earnings
• Companies that can be bought at a reasonable price
• Companies with an “economic moat,” or a unique competitive advantage

With an expense ratio of 0.47%, the VanEck Morningstar Wide Moat ETF (BATS: MOAT) tracks companies with sustainable competitive advantages. That includes names such as Estee Lauder (NYSE: EL), Teradyne (NASDAQ: TER), Boeing (NYSE: BA), Alphabet, Nike (NYSE: NKE), and NXP Semiconductors (NASDAQ: NXPI). These are firms that tend to perform relatively well even during uncertain economic periods.

The MOAT ETF also yields 1.29% and pays a yearly dividend. On December 24, it paid out $1.2675. On December 22, 2023, it paid $0.7285. While the yield is modest, the focus here is on long-term quality and resilience.

Schwab U.S. Dividend Equity ETF (SCHD): Reliable Income Stream

There’s also the Schwab US Dividend Equity ETF (NYSEARCA: SCHD), which tracks the performance of 100 high-yielding dividend stocks selected based on yield and five-year dividend growth rates.

With an expense ratio of 0.06%, the ETF tracks the total return of the Dow Jones U.S. Dividend Index. It also yields 3.37%, about three times the S&P 500’s dividend yield, making it particularly attractive to income-focused investors. Its holdings include Amgen (NYSE: AMGN), AbbVie (NYSE: ABBV), Home Depot (NYSE: HD), Cisco Systems (NASDAQ: CSCO), Broadcom (NASDAQ: AVGO), Chevron (NYSE: CVX), UPS (NYSE: UPS), and Coca-Cola (NYSE: KO).

Safe ETFs Can Help You Stay Invested

At the end of the day, investing during periods of uncertainty isn’t about trying to perfectly time the market—it’s about positioning yourself to weather the storm while still staying invested. Safe ETFs like VOO, MOAT, and SCHD offer a balanced mix of broad market exposure, high-quality companies, and reliable income, which can help smooth out the ride when volatility spikes.

While no investment is completely risk-free, sticking with diversified, low-cost ETFs and focusing on long-term fundamentals can make a meaningful difference. Instead of reacting emotionally to headlines, investors may be better served by staying disciplined, maintaining perspective, and letting proven strategies work over time.

The results mark yet another milestone in AbbVie’s post-Humira transformation. Just three years removed from the January 2023 loss of U.S. exclusivity on what was once the world’s best-selling drug, the company has executed one of the most successful franchise transitions in modern pharmaceutical history. Immunology revenues alone reached $7.3 billion — nearly three times Humira’s remaining global contribution — while the neuroscience segment surged 26% to $2.9 billion, reflecting the growing breadth of AbbVie’s growth platform.

Management raised full-year 2026 adjusted EPS guidance to a range of $14.08–$14.28, up from the prior range of $13.96–$14.16, and lifted full-year revenue guidance to approximately $67.3 billion, implying roughly 10% top-line growth for the full year. For investors watching ABBV, the message from Q1 is unambiguous: the diversified growth engine is firing.

Immunology and Neuroscience Power the Beat

The immunology portfolio remains AbbVie’s defining growth engine, and Q1 2026 results reinforced that thesis with authority. Global Skyrizi revenues reached $4.483 billion, up 30.9% on a reported basis and 29.2% operationally, as the drug continues to expand across its approved indications in plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Rinvoq added $2.119 billion in revenues, growing 23.3% reported and 20.2% operationally, as prescriptions in atopic dermatitis, rheumatoid arthritis, and other inflammatory indications accelerated. Together, Skyrizi and Rinvoq generated more than $6.6 billion in a single quarter — a run rate that has already surpassed AbbVie’s own long-term 2027 combined guidance target issued just a few years ago.

Humira, now firmly in managed decline, contributed $688 million globally — a 38.6% reported decrease — but that erosion was entirely expected and is increasingly immaterial relative to the scale of its successors. The immunology segment’s adjusted operating margin held firm, reflecting AbbVie’s pricing discipline and mix shift toward higher-margin next-generation therapies.

Neuroscience delivered arguably the quarter’s most impressive segment result: $2.875 billion in revenues, up 26.0% reported. Botox Therapeutic crossed $1 billion for the quarter for the first time, growing 16.5%. The migraine franchise saw explosive growth, with Qulipta up 53.6% and Ubrelvy up 41.4%. Vraylar contributed $905 million, up 18.4%, continuing its steady expansion in bipolar depression and schizophrenia.

Pipeline and Strategic Investments Add Long-Term Optionality

Beyond the headline numbers, AbbVie used Q1 to materially advance its pipeline and signal confidence in long-term manufacturing capacity. The company submitted a supplemental FDA application for Skyrizi subcutaneous induction in Crohn’s disease — a potential label expansion that would offer a more convenient dosing option supported by the positive Phase 3 AFFIRM data, with an approval decision expected later this year. Separately, AbbVie filed for a new Rinvoq indication in severe alopecia areata, backed by the Phase 3 UP-AA program, further extending the drug’s addressable market.

In oncology, the FDA approved the Venclexta plus acalabrutinib combination as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia — a clinically and commercially significant milestone. Early-stage pipeline also gained attention: ABBV-295, a non-incretin obesity candidate, showed clinically meaningful weight reduction at week 12 in a Phase 1 multiple ascending dose study, with a favorable tolerability profile.

While still early, obesity represents a potentially enormous long-term opportunity. On the manufacturing front, AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical campus in Durham, North Carolina, alongside $380 million in new API facilities in North Chicago — investments in AI-integrated production that position the company to scale its immunology and neuroscience franchises well into the next decade.

Technical Analysis: Post-Earnings Rally Faces a Critical Test

ABBV closed May 1, 2026, at $211.32, up 3.64% on the session following the earnings beat, with volume registering 10.32 million shares — elevated relative to recent averages. The daily candlestick chart shows the stock rebounding sharply from an April low near $188, recovering toward the 50-day SMA, which is declining and currently sits at $214.89 — just above the current price. This places ABBV in a technically critical zone: the post-earnings pop brings the price back to a meaningful resistance level, but the stock has not yet reclaimed the 50-day SMA.

The broader trend since the October 2025 high near $247 has been a series of lower highs and periodic tests of support, with the $210 horizontal zone — visible as a dotted support line on the chart — acting as a key battleground. A sustained close above the 50-day SMA at $214.89 would be a constructive signal. Failure to hold $210 on any pullback, however, would re-expose the $195–$200 range. The $312 long-term SMA represents a significantly longer-term technical level that underscores just how far the stock has compressed from peak valuations, and a sustained fundamental re-rating would be required to reclaim that territory.

Risks to Growth

Despite the strong Q1 print, investors should monitor several meaningful headwinds. Humira erosion, while managed, is expected to continue with global revenues guided toward $2.9 billion for full-year 2026. That was roughly half of its pre-biosimilar contribution. In aesthetics, Juvederm declined 2.9% operationally as macroeconomic pressures weigh on discretionary spending in key dermal filler markets, and category growth is expected to remain challenged in the near term.

The FDA issued a Complete Response Letter for trenibotE on manufacturing grounds, delaying what could have been a meaningful catalyst for aesthetics into 2027. Imbruvica continues its structural decline, down 24.7% in Q1, as competitive erosion in the CLL market intensifies. Lastly, the FDA’s selection of Botox Therapeutic for Medicare price negotiation in 2028 introduces a longer-dated pricing overhang on one of AbbVie’s most durable revenue streams. Large IPR&D charges ($744 million in Q1 alone) also create noise around GAAP earnings and could recur with future pipeline investments.

AbbVie Stock Outlook: Growth Momentum Meets Key Resistance

AbbVie’s Q1 2026 results confirm that its post-Humira growth platform is accelerating. Skyrizi and Rinvoq are growing well ahead of original guidance targets, neuroscience is emerging as a genuine second growth pillar, and management’s decision to raise full-year guidance reflects earned confidence rather than promotional optimism.

The stock’s 3.64% earnings-day gain brings ABBV back toward a decisive technical level: the declining 50-day SMA at $214.89. A sustained reclaim of that average, along with continued execution in immunology and neuroscience, would set the stage for a broader re-rating. The $312 long-term SMA remains a distant but important benchmark. That level signals the degree of multiple compression since peak Humira-era valuations, as well as the magnitude of the re-rating opportunity if AbbVie continues to deliver. Until then, $210–$215 is the zone to watch.

Dividend Aristocrats are widely considered some of the highest-quality companies in the market. To earn this title, a company must have increased its dividend payouts for at least 25 consecutive years. Dividend Kings take that standard even further. These elite companies have raised their dividends for 50 years or more, proving their resilience across multiple economic cycles.

What makes these companies particularly compelling is their ability to perform in virtually any environment. Whether facing inflation, recessions, rising interest rates, market crashes, or economic booms, they have consistently rewarded shareholders with growing income. That kind of durability is rare—and valuable. It also reflects strong management teams, disciplined capital allocation, and business models built to withstand long-term pressure.

Simply put, if a company can survive decades of economic uncertainty and still pay—and raise—dividends, it deserves attention.

There’s just one drawback: there isn’t currently a dedicated ETF focused solely on Dividend Kings. That means investors looking for exposure must either purchase individual stocks or turn to ETFs that emphasize similar high-quality, dividend-growing companies.

Here are three strong ETF options to consider.

A Pure Play on Dividend Aristocrats

The ProShares S&P 500 Dividend Aristocrats ETF (BATS: NOBL) offers direct exposure to companies that have increased dividends for at least 25 consecutive years.

With an expense ratio of 0.35% and a yield of approximately 2.05%, NOBL tracks the S&P 500 Dividend Aristocrats Index. The fund focuses on stable, high-quality businesses with long track records of dividend growth—many of which have been increasing payouts for 40 years or more.

Its holdings include well-known companies such as Caterpillar (NYSE: CAT), Pentair (NYSE: PNR), AbbVie (NYSE: ABBV), Aflac (NYSE: AFL), General Dynamics (NYSE: GD), Clorox (NYSE: CLX), Walmart (NASDAQ: WMT), and Hormel Foods (NYSE: HRL).

These companies have demonstrated consistent performance and income reliability, making NOBL a strong choice for conservative, income-focused investors.

Low-Cost Exposure to High-Quality Value Stocks

Another solid option is the Schwab U.S. Large Cap Value ETF (NYSEARCA: SCHV), which focuses on large-cap value stocks.

SCHV stands out for its ultra-low expense ratio of just 0.04%, making it one of the most cost-effective ETFs available. It also offers a yield of about 1.85% and provides exposure to a diversified basket of financially strong companies.

Top holdings include Berkshire Hathaway (NYSE: BRK.B), Johnson & Johnson (NYSE: JNJ), Exxon Mobil (NYSE: XOM), JPMorgan Chase (NYSE: JPM), Home Depot (NYSE: HD), AbbVie, Pfizer (NYSE: PFE), and Merck & Co. (NYSE: MRK).

High Yield Meets Dividend Growth Discipline

The Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) is another popular choice among income investors. With an expense ratio of 0.06% and a yield of roughly 3.5%, SCHD tracks the Dow Jones U.S. Dividend 100 Index. The ETF focuses on companies with strong fundamentals, sustainable dividends, and a history of consistent payouts.

Its holdings include industry leaders such as Amgen (NASDAQ: AMGN), AbbVie, Home Depot, Cisco Systems (NASDAQ; CSCO), Broadcom (NASDAQ: AVGO), Chevron Corporation (NYSE: CVX), United Parcel Service (NYSE: UPS), and The Coca-Cola Company (NYSE: KO).

SCHD is particularly appealing for investors seeking a blend of income, quality, and long-term growth potential.

Dividend ETFs Offer Stability in Any Market

In uncertain markets, stability and income become even more important. Dividend-focused ETFs—especially those emphasizing companies with long histories of growing payouts—can help anchor your portfolio.

These funds don’t just provide income—they offer exposure to businesses that have proven their ability to navigate inflation, recessions, and shifting interest rate environments. That kind of consistency can reduce volatility while still allowing for long-term capital appreciation.

While no ETF is exclusively dedicated to Dividend Kings, funds like NOBL, SCHV, and SCHD give investors access to many of the same high-quality characteristics: strong balance sheets, disciplined management, and shareholder-friendly capital allocation.

For investors looking to balance risk and reward, these ETFs can serve as a core portfolio holding—delivering both reliability and growth potential over time.

In today’s market environment, where interest rates and inflation expectations continue to shift, investors are increasingly looking for flexible income strategies that don’t rely on a single asset class. Dividend ETFs stand out because they combine equity upside with regular income, offering a middle ground between growth investing and traditional fixed income. This flexibility makes them especially attractive for long-term investors navigating uncertain conditions.

For investors looking to simplify their portfolios while still generating reliable cash flow, dividend-focused ETFs can serve as strong core holdings.

Three funds in particular stand out for long-term, buy-and-hold investors: The Vanguard Real Estate ETF (NYSEARCA: VNQ), the ProShares S&P 500 Dividend Aristocrats ETF (BATS: NOBL), and the Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD). Each offers a different approach to income and stability, but all share a focus on quality and long-term compounding.

The Vanguard Real Estate ETF (VNQ)

The Vanguard Real Estate ETF (VNQ) provides broad exposure to the U.S. real estate market through a diversified portfolio of real estate investment trusts and related companies. 

With an expense ratio of just 0.13% and a dividend yield of roughly 3.7%, it remains one of the most cost-effective ways to gain exposure to the property sector. 

The fund holds more than 150 positions, spanning healthcare REITs, industrial warehouses, data centers, and retail properties. Major holdings include Welltower (NYSE: WELL), Prologis (NYSE: PLD), American Tower Corporation (NYSE: AMT), Equinix (NASDAQ: EQIX), Digital Realty Trust (NYSE: DLR), and Simon Property Group (NYSE: SPG).

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL)

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) tracks companies in the S&P 500 that have increased their dividends for at least 25 consecutive years, a group often viewed as some of the most financially stable businesses in the market. 

With an expense ratio of around 0.35% and a dividend yield near 2.5%, NOBL is less about high income and more about durability and steady growth. It holds roughly 69 companies, including AbbVie (NYSE: ABBV), Lowe’s (NYSE: LOW), Archer Daniels Midland (NYSE: ADM), and Pentair (NYSE: PNR). These businesses have demonstrated an ability to withstand economic downturns while continuing to reward shareholders, making the ETF a popular choice for investors who prioritize long-term reliability over short-term yield.

The Schwab U.S. Dividend Equity ETF (SCHD) 

The Schwab U.S. Dividend Equity ETF (SCHD) offers a balance between income, quality, and cost efficiency. With an extremely low expense ratio of 0.06% and a dividend yield close to 4%, SCHD has become one of the most widely held dividend ETFs among long-term investors. It tracks a portfolio of more than 100 U.S. companies with strong balance sheets, consistent cash flow, and a history of paying dividends.

Holdings include well-known names such as Amgen (NASDAQ: AMGN), AbbVie, Home Depot (NYSE: HD), Cisco Systems (NASDAQ: CSCO), Chevron (NYSE: CVX), and Coca-Cola (NYSE: KO). What makes SCHD particularly appealing is its blend of defensive and cyclical sectors, giving investors exposure to both stability and growth potential while maintaining a strong income stream.

Why These ETFs Work for Long-Term Investors

Funds like VNQ, NOBL, and SCHD demonstrate that a disciplined, income-focused approach can provide both stability and growth over time. By combining real estate exposure, dividend consistency, and high-quality U.S. equities, these ETFs offer a well-rounded foundation for investors who want to generate passive income while benefiting from compounding returns. For those willing to stay patient and reinvest dividends, these types of core holdings can play a powerful role in achieving financial independence 

Importantly, these ETFs also remove the need to constantly monitor individual holdings or time the market. That simplicity allows investors to stay focused on long-term goals rather than short-term volatility, which is often the biggest determinant of successful outcomes.

There are many safe ETFs to choose from. So many, in fact, that it can create analysis paralysis. Don’t let that happen to you. Here are three of the top ETFs to own if stable growth with a reliable yield is your first priority.

Safe ETFs to Buy: The Vanguard S&P 500 ETF

“Over the years, I’ve often been asked for investment advice,” Buffett wrote in a 2016 shareholder letter. “My regular recommendation has been a low-cost S&P 500 index fund.”

With that, Buffett has named the Vanguard S&P 500 ETF (NYSEARCA: VOO) as one way to invest. What makes the VOO ETF the most attractive is that it measures the performance of the S&P 500 and includes both value stocks and growth stocks from multiple market sectors. In fact, its holdings include some of the most widely held stocks, including Nvidia (NASDAQ: NVDA), Microsoft (NASDAQ: MSFT), Apple (NASDAQ: AAPL), Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOGL) and Berkshire Hathaway (NYSE: BRK.B).

It offers a low-cost way to safely diversify by tracking the largest companies, making it an ideal set-it-and-forget-it trade. In addition, with an expense ratio of 0.03%, the ETF also pays a quarterly yield. On December 24, it paid a dividend of just over $1.771. Before that, it paid a dividend of $1.74 on October 1. Before that, it paid a dividend of just over $1.7447 on July 2.

Safe ETFs to Buy: The VanEck Morningstar Wide Moat ETF

If you follow Warren Buffett, you know he likes companies with a wide economic moat. In fact, if you want to invest in companies attractive to the billionaire, make sure they are:

• Simple companies that are easy to understand
• Companies with predictable and proven earnings
• Companies that can be bought at a reasonable price
• Companies with “economic moat,” or a unique advantage over their competition.

With an expense ratio of 0.47%, the VanEck Morningstar Wide Moat ETF (BATS: MOAT) tracks the performance of companies with sustainable competitive advantages. That includes Estee Lauder (NYSE: EL), Teradyne (NASDAQ: TER), Boeing (NYSE: BA), Alphabet, Nike (NYSE: NKE), and NXP Semiconductors (NASDAQ: NXPI). 

The MOAT ETF also yields 1.29% and pays a yearly dividend. On December 24, it paid out a dividend of $1.2675. On December 22, 2023, it paid out a dividend of $0.7285.

Safe ETFs to Buy: The Schwab US Dividend Equity ETF

There’s also the Schwab US Dividend Equity ETF (NYSEARCA: SCHD), which tracks the performance of 100 high-yielding dividend stocks chosen by yield and five-year dividend growth rates.

With an expense ratio of 0.06%, the ETF tracks the total return of the Dow Jones U.S. Dividend Index. It also yields 3.37%, which is about three times the S&P 500’s dividend yield, and has holdings in names such as: Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), Home Depot (NYSE: HD), Cisco Systems (NASDAQ; CSCO), Broadcom (NASDAQ: AVGO), Chevron (NYSE: CVX), UPS (NYSE: UPS), and Coca-Cola (NYSE: KO).  Its last dividend of just over 27 cents was paid on December 15. Before that, it paid just over 26 cents on September 29. 

Control What You Can Control

While geopolitical tensions and market volatility may keep investors on edge, the key to long-term success is staying invested in high-quality assets. ETFs like the Vanguard S&P 500 ETF, VanEck Morningstar Wide Moat ETF, and Schwab US Dividend Equity ETF provide diversification, strong underlying companies, and reliable income streams—all qualities that can help weather uncertain markets. 

Instead of trying to time every headline, investors can focus on disciplined, long-term strategies using funds like these to build resilience and stability in their portfolios.

After spending years building up your nest egg, you want to step into the retirement you deserve — whether that means relocating to a dream destination, traveling more, spending more time with family, or simply enjoying the comfort of your finances.

What you don’t want is constant stress about market swings, inflation quietly eroding your purchasing power, or the fear of outliving your savings. Retirement should be about freedom and confidence, not anxiety.

One of the most effective ways to build that confidence is by owning income-focused ETFs that deliver consistent cash flow, diversification, and professional management. Instead of relying solely on selling shares to fund your lifestyle, these funds aim to turn your portfolio into a dependable income engine.

Below are five retirement income ETFs that can help provide a reliable “paycheck” in retirement, along with why each can play an important role in a long-term income strategy.

Retirement Income ETFs: Schwab US Dividend Equity ETF (SCHD)

Retirees looking for a low-cost dividend ETF that invests in quality companies can look into the Schwab US Dividend Equity ETF (NYSEARCA: SCHD). This ETF screens for high-yielding companies that have a track record of paying dividends. 

The ETF tracks the total return of the Dow Jones U.S. Dividend 100 Index. It has 100 holdings, including names such as Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), Home Depot (NYSE: HD), Cisco Systems (NASDAQ: CSCO), Broadcom (NASDAQ: AVGO), Chevron (NYSE: CVX), UPS (NYSE: UPS), and Coca-Cola (NYSE: KO).  

The fund has an expense ratio of 0.06% and pays a quarterly dividend that yields 3.38%.

Retirement Income ETFs: Invesco S&P 500 High Dividend Low Volatility ETF (SPHD)

The Invesco S&P 500 High Dividend Low Volatility ETF (NYSEARCA: SPHD) seeks steady income by investing in high-quality companies that pay high dividends and experience low volatility, helping steer investors clear of value traps and mitigate risk.

The fund offers a yield of about 4%. This means a $400,000 investment could pay $1,333 a month with that yield. Its holdings are mainly in real estate and in defensive sectors such as consumer staples and utilities.

Retirement Income ETFs: JPMorgan Equity Premium Income ETF (JEPI)

The JPMorgan Equity Premium Income ETF (NYSEARCA: JEPI) generates income by combining some of the top blue-chip stocks, such as Amazon (NASDAQ: AMZN), Mastercard (NYSE: MA), and Nvidia (NASDAQ: NVDA), using options strategies.

All of which help produce hefty monthly income for investors. In fact, last checked, the JEPI ETF yields about 7.24%, which isn’t too shabby at all. With an expense ratio of 0.35%, the ETF holds 122 stocks, including Visa (NYSE: V), Mastercard, Trane Technologies (NYSE: TT), Microsoft (NASDAQ: MSFT), Oracle (NYSE: ORCL), The Southern Company (NYSE: SO), and Nvidia.

Retirement Income ETFs: JPMorgan Nasdaq Equity Premium Equity Income ETF (JEPQ)

The JPMorgan Nasdaq Equity Premium Equity Income ETF (NASDAQ: JEPQ) generates income by selling options and by investing in U.S. large-cap growth stocks. All of which allows it to deliver a monthly income stream through options premiums and stock dividends. Even better, investors have also benefited from the ETF’s appreciation. 

The ETF has an expense ratio of 0.35% at the time of this writing, and pays a monthly dividend with a yield of 9.74%,

Retirement Income ETFs: iShares Core High Dividend ETF (HDV)

The iShares Core High Dividend ETF (NYSEARCA: HDV) tracks the investment results of an index composed of relatively high-dividend-paying U.S. equities. Some of its top holdings include Exxon Mobil (NYSE: XOM), Chevron, and Johnson & Johnson (NYSE: JNJ).

With a yield of 3.41% and an expense ratio of 0.08%,

It’s About Peace of Mind

Retirement isn’t about chasing the highest returns or trying to beat the market. It’s about peace of mind. It’s about knowing your bills are covered, your lifestyle is supported, and your money is working quietly in the background so you can focus on living.

The right mix of retirement income ETFs can help turn decades of hard work into dependable cash flow — month after month, year after year. While no investment is risk-free, building a diversified portfolio centered on quality, income, and consistency can go a long way toward making retirement feel less uncertain and more secure. In the end, the goal isn’t just to retire — it’s to retire confidently, knowing your portfolio is built to support the life you’ve earned.

So, with AbbVie off to a slow start to 2026, it’s a natural signal to at least consider the contrarian bullish position. What’s more, ABBV stock has been deflated for some time. In the past 30 days, it’s off course by more than 5%. Since the close of the Oct. 1 session, the equity is down roughly 12%.

Historically, the healthcare juggernaut tends to bounce back from extended downside, and that’s really the narrative that we have before us. Not only that, a positive surprise for its upcoming fourth-quarter earnings report could reinvigorate sentiment for ABBV stock.

Analysts are looking for earnings per share to hit $2.92 on revenue of $16.39 billion when AbbVie discloses results on Feb. 4. In the year-ago quarter, the company posted EPS of $2.16 on revenue of $15.1 billion, missing the consensus EPS target of $2.26 but exceeding the sales forecast of $14.83 billion.

Still, despite the mixed results, ABBV stock popped higher following the disclosure. While it’s impossible to say with absolute certainty how events may transpire two weeks from now, the setup is awfully enticing.

How the Options Market Offers a Contrarian Skew for ABBV Stock

One of the more insightful screeners that short-term traders should consider is volatility skew. This readout shows how implied volatility (IV) — which reveals the expected kinesis of the target security based on actual order flows — differs across various strike prices for the same expiration date.

What we’re looking for is the volatility smile. In the case of ABBV stock, puts for the Feb. 20 options chain feature a higher IV in the lower strike price ranges than calls, meaning that the smart money is effectively paying a more robust premium for downside insurance (or outright bearish speculation).

On the flipside, the above dynamic leaves call options relatively underpriced relative to puts. Therefore, if we have a good reason to go with the contrarian trade, ABBV stock could be mispriced in our favor. Essentially, we could take advantage of an expectational arbitrage.

We’ll get there in a second. For the Feb. 20 expiration date, the Black-Scholes model — which is Wall Street’s standard mechanism for pricing options — reveals that the expected move for ABBV stock is between $202.96 and $229.12, representing a 6.05% high-low spread from the spot price.

At first glance, this dispersion seems insightful, and honestly, it provides the parameters of the trading battlegrounds. However, we’re left in the dark as to where in this wide spectrum of prices ABBV stock is most likely to congregate at expiration.

Primarily, the challenge is that Black-Scholes assumes a perfect, risk-neutral world where outside context doesn’t influence forward probabilities. So, in this world, a three-pointer is always more difficult to make than a layup due to the greater distance to the basket.

However, real-world situations don’t work so neatly. After all, the opposing team isn’t just going to let you walk up and get an uncontested shot in. Due to different dynamics found in actual games, the probability of a scoring effort is best determined by context rather than distance.

Leveraging the Markov Property for the Financial Markets

It might seem that I’m critical of the Black-Scholes model, which would be an untrue claim. What makes Black-Scholes so special is that it’s a uniform, standard template that everyone has essentially agreed to use. When I say that it doesn’t consistently reflect reality, that is a well-known limitation. However, before we start nitpicking its findings, we must first have a frame of reference.

Like it or not, Black-Scholes provides that frame of reference. Still, as analysts, our job is to determine whether the model is the most optimal representation of forward probabilities for a given options chain. In my opinion, certain ABBV call options could be underpriced, allowing us to possibly scalp some profits.

Where the mispricing becomes discernible is through a second-order analysis using the Markov property. Under Markov, the future state of a system depends only on the current state. Put simply, everything is contextual. Going back to my earlier basketball analogy, a three-pointer could actually be the statistically easier shot to make if the route to a layup is heavily defended.

When it comes to ABBV stock, the current context is that the security, in the last 10 weeks printed only four up weeks, thereby leading to a downward slope. Under this quantitative setup, the forward 10-week returns would likely land between $212.50 and $232.50.

To be fair, this spectrum is wide and doesn’t materially improve from the expected dispersion of between $203 and $229 under the Black-Scholes model. But the beauty of the Markovian hierarchical approach is probability density. Over many trials of the 4-6-D sequence (44 rolling trials since January 2019), we would expect ABBV stock to cluster most prominently between $218 and $226 over the next 10 weeks.

Even better, this distribution wouldn’t be expected to shift dramatically over the next five weeks, coinciding with the Feb. 20 options chain. Plus, the speculation is that a better-than-expected earnings report could help boost momentum, making ABBV stock a compelling contrarian candidate.

Letting the Numbers Build the Trade

Armed with the market intelligence above, the trade that would appear to make the most sense is the 220/230 bull call spread expiring Feb. 20. This wager involves two simultaneous transactions on a single ticket (execution): buy the $220 call and sell the $230 call, for a net debit paid of $402 (the most that can be lost).

Should ABBV stock rise through the $230 strike at expiration, the maximum profit would be $598, a payout of nearly 149%. Breakeven lands at $224.02, enhancing the trade’s probabilistic credibility.

To be sure, the $230 strike falls near the bullish end of the distribution, which means it’s an awfully ambitious target. However, the breakeven price sits close to the center of peak probability density under 4-6-D conditions. With any luck, AbbVie may deliver a strong earnings print, which could make this spread a lucrative proposition.

But what should you look for? Let’s take as a given that investors should look for stocks with a dividend yield of around 3%. The most recent, if not necessarily reliable, inflation data we have puts inflation around 2.7%. It’s too early to tell if inflation will increase as monetary power loosens and stimulus is added to the economy. Nevertheless, a dividend of at least 3% will be needed to keep your investments ahead of inflation. 

These stocks provide investors with the benefit of reliable quarterly distributions that you can accept as cash in your bank account or that you can reinvest to increase your position in the stock.  

However, you should expect more from dividend stocks than reliable income. The stocks on this list also have a history of delivering a solid total return, which includes stock price appreciation to go along with a growing dividend. That’s how you maximize the benefits of compounding.  

Dividend Stocks to Buy: AbbVie

AbbVie Inc. (NYSE: ABBV) is hardly considered a comeback story. ABBV stock is up nearly 30% in 2025, and analysts are raising their price targets for the next 12 months. Outside of a company like Eli Lilly & Co. (NYSE: LLY), which is in a dominant position in the GLP-1 market, it’s been a rough year for pharmaceutical stocks. 

The key for AbbVie is that the company has successfully replaced the revenue it’s losing as its blockbuster Humira drug reached the patent cliff. But AbbVie’s patent-protected Skyrizi and Rinvoq are picking up the slack, and the company has a deep pipeline and a robust balance sheet that gives the company the firepower to get them across the finish line. 

AbbVie is also a dividend king, meaning it’s increased its dividend for at least 50 consecutive years. The yield as of this writing is 2.84% and is well covered by the company’s cash flow.  

Dividend Stocks to Buy: Bristol-Myers Squibb 

Bristol-Myers Squibb Co. (NYSE: BMY) has had a challenging few years as investors have cooled on large pharmaceutical names facing patent expirations. But value-minded dividend investors may find an opportunity as the stock appears deeply discounted relative to its historical valuation. The company trades at a forward P/E under 10 and offers a dividend yield in the 4.9% range—well above the market average. 

The fundamentals remain solid. Bristol-Myers is focusing on expanding newer drugs like Eliquis, Opdivo, and Reblozyl while investing in its pipeline of oncology and immunology therapies. Near-term results may stay lumpy, but with a steady cash flow profile and consistent earnings support, the dividend looks safe.

For contrarian investors, BMY provides a classic example of a high-yield stock with stabilization and upside potential if sentiment improves in 2026. 

Dividend Stocks to Buy: Pepsi 

PepsiCo Inc. (NASDAQ: PEP) offers a blend of income reliability and defensive growth that fits well in a 2026 portfolio rotation. While consumer staples stocks have lagged during the speculative surge into AI and tech, that underperformance has set the stage for better entry points. PepsiCo’s diversified product portfolio, from beverages to snacks, gives it pricing power and resilience even in a slower economy. 

The company has increased its dividend for more than 50 years, placing it among the Dividend Kings. Its yield of roughly 3% is comfortably above inflation, and its payout ratio of around 70% indicates room for further growth. As input cost pressures ease and global demand normalizes, PepsiCo looks positioned for mid-single-digit earnings growth alongside continued capital returns. 

Dividend Stocks to Buy: Enbridge 

Next on my list is Enbridge Inc. (NYSE: ENB), which is an energy infrastructure company. For starters, Enbridge has a high-yield dividend of 5.66% as of December 26. An above average yield can be a value trap, but that doesn’t appear to be the case with Enbridge.  

The catalyst is likely to be the company’s positioning with heavy crude oil. This is the type of crude oil needed for applications like diesel fuel. Unlike light crude oil, heavy crude inventories are low. That means countries with heavy oil resources, such as Canada, will benefit.  

Enbridge is the largest transporter of Western Canadian select. And the company has long-term contracts, a stable tolling model, and expansion opportunities that give investors exposure without the upstream risk.  

Dividend Stocks to Buy: Texas Instruments 

Texas Instruments Inc. (NASDAQ: TXN) stands out in the semiconductor space as one of the most dependable dividend payers. While many chipmakers lean heavily on cyclical end markets, TI’s strategy focuses on analog and embedded chips used in long-duration industrial and automotive applications—segments that provide stable, recurring demand. 

The company has raised its dividend for 20 consecutive years, and at a current yield near 3.3%, TXN offers an appealing blend of income and long-term growth. With its disciplined capital allocation, massive free cash flow generation, and conservative balance sheet, Texas Instruments embodies the kind of steady compounder that dividend investors can hold through multiple market cycles. 

The Bottom Line on High-Powered Dividend Stocks for 2026 

As the market transitions from speculative tech toward more income-focused investing, dividend stocks are regaining their appeal. The five companies highlighted here: AbbVie, Bristol-Myers Squibb, PepsiCo, Enbridge, and Texas Instruments, combine reliable dividend growth with the potential for solid total returns. 

They operate in diverse sectors, ranging from healthcare and consumer staples to energy and semiconductors, providing investors with balance and resilience across different market conditions. In 2026, when interest rates may finally stabilize and inflation holds near current levels, long-term dividend payers like these could quietly outperform, rewarding patient investors with steady income and compounding gains over time.